Phase I/II Study to Investigate the Safety, Tolerability, Efficacy and Pharmacokinetics of ZK 219477 in Combination With Cisplatin as First-Line Therapy in Chemotherapy-naïve Patients With Extensive-Disease (ED) Stage Small-Cell Lung Cancer (SCLC).

Trial Profile

Phase I/II Study to Investigate the Safety, Tolerability, Efficacy and Pharmacokinetics of ZK 219477 in Combination With Cisplatin as First-Line Therapy in Chemotherapy-naïve Patients With Extensive-Disease (ED) Stage Small-Cell Lung Cancer (SCLC).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Nov 2014

At a glance

  • Drugs Sagopilone (Primary) ; Cisplatin
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bayer HealthCare Pharmaceuticals
  • Most Recent Events

    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database).
    • 22 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Jun 2009 Actual patient number (26) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top